Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

For those who are new to the company, we have a focus in cardiovascular diseases with in vivo gene editing and where we take the CRISPR/Cas9 components, encapsulate it in a LNP particle ...

Intellia Therapeutics' most advanced product candidates, NTL-2002 and Next-z, are aimed as in vivo gene therapies, using Crispr/Cas9 encapsulated in their proprietary LNP, which after being ...

unlike other technologies like CRISPR/Cas9. BEAM-101 modifies haematopoietic stem cells to express foetal haemoglobin (HbF), rather than the mutated form of the protein (HbS) seen in SCD patients.

Every time a shuttle docks with the International Space Station (ISS), a delicate dance unfolds between the shuttle's docking system and its counterpart on the station. Thanks to international ...

Moreover, Editas has reported promising preclinical results with its LNP formulations ... short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded ...

Clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9)-mediated technology ... we need to move away from AAVs and LNP delivery technologies and use other ...

Her lab, in collaboration with Gaurav Sahay, Ph.D. at Oregon State University, is focusing on the development of lipid nanoparticle (LNP) delivery systems—a ... 1/2 clinical trial evaluating an in ...